Therapy of type 2 diabetes, cardiovascular death, and the UGDP

American Heart Journal

Volumn 138, Issue 5 I, 1999, Pages

  Feinglos, M N ^a   Bethel, M A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; INSULIN ZINC SUSPENSION; TOLBUTAMIDE;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DRUG SENSITIVITY; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN TREATMENT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0032744557     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70034-7     Document Type: Conference Paper

References (22)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19:789-830.
3. Feinglos MN, Bethel MA. The treatment of type 2 diabetes mellitus. Med Clin North Am 1998;82:757-89.
4. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.
5. Schotborgh CE, Wilde AM. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997;34:73-80.
6. Smits P, Bijlstra PJ, Russel FGM, et al. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Pract 1996;31(suppl):S55-9.
7. Heine RJ. Role of sulfonylureas in non-insulin-dependent diabetes mellitus, II: "the cons." Horm Metab Res 1996;28:522-6.
8. Jollis JG, Simpson RJ Jr, Cascio WE, et al. The relation between sulfonylurea therapy, complications, and outcome for elderly acute myocardial infarction patients. Am Heart J 1998;138:S376-80.
9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;52:837-53.
10. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: Harris MI, Cowie CC, Reiber G, et al, editors. Diabetes in America. 2nd ed. Washington, DC: US Department of Health and Human Services; 1995. p 519-39. NIH publication No. 95-1468.
11. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996;124(1 pt 2):110-6.
12. Genuth S. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 pt 2):104-9.
13. Knatterud GL, Klimt CR, Levin ME, et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, VII: mortality and selected nonfatal events with insulin treatment. JAMA 1978;240:37-42.
14. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, VIII: evaluation of insulin therapy: final report. Diabetes 1982;31(suppl 5):1-78.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998;21(suppl 1):S5-19.
16. Harris MI. Summary. In: Harris MI, Cowie CC, Reiber G, et al, editors. Diabetes in America. 2nd ed. Washington, DC: US Department of Health and Human Services; 1995. p. 1-13. NIH publication No. 95-1468.
17. Feinstein AR. Clinical biostatistics, VIII: an analytic appraisal of the University Group Diabetes Program (UGDP) study. Clin Pharmacol Ther 1971;12:167-91.
18. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA 1980;243:450-7.
19. Bradley RF, Dolger H, Forsham PH, et al. Settling the UGDP controversy? JAMA 1975;232:813-7.
20. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Reiber G, et al, editors. Diabetes in America, 2nd ed. Washington, DC: US Department of Health and Human Services; 1995. p. 429-48. NIH publication No. 95-1468.
21. Abraira C, Johnson N, Colwell J, and the VA CSDM Group. VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): results of the completed feasibility trial. Diabetes 1994;43(suppl):59A.
22. American Diabetes Association. Position statement: standards of medical care for patients with diabetes mellitus. Diabetes Care 1998;21:S23-31.